The Company
Hyalose was founded in August 2000 to commercialize the unique
recombinant technology of Dr. Paul DeAngelis and Dr. Paul Weigel.
The company seeks partnerships and collaborations with pharmaceutical
companies and other market specialists to take new therapeutics
in cancer treatment, medical device coatings, carbohydrate drug
targets and other applications to market.
Management
Co-Chief Scientists
ETI Management
Portfolio Company Personnel
Hyalose L.L.C., is an Emergent Technologies Inc. (ETI) portfolio company and ETI provides all management services and operations support.
About Emergent Technologies, Inc.
Headquartered in Austin, Texas, Emergent Technologies, Inc. (ETI) is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. The Company creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables the Company to select promising scientific discoveries for development, maximize the value of intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website www.etibio.com |
